Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations (Temporarily Closed)
Study Number: EA5162 (Temporarily Closed)
This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Navigator Ashton, 309-243-3611 firstname.lastname@example.org
- Amanda , 309-243-3663, email@example.com
- Jessica, 309-243-3615, firstname.lastname@example.org